SAN Sanofi

Sanofi names new leaders to Executive Committee

Sanofi names new leaders to Executive Committee

Sanofi names new leaders to Executive Committee

  • Natalie Bickford appointed Chief People Officer
  • Arnaud Robert appointed Chief Digital Officer
  • Julie Van Ongevalle appointed Head of Consumer Healthcare
  • Thomas Triomphe appointed Head of Sanofi Pasteur



PARIS – May 29, 2020 - Sanofi has named four new leaders to its Executive Committee. These appointments now complete the announced changes in February to further simplify the Company’s executive leadership team.

The complete Sanofi Executive Committee now includes the four heads of the Company’s global business units (Sanofi Genzyme, Sanofi Pasteur, General Medicines, and Consumer Healthcare) as well as the global Heads of Research and Development, Industrial Affairs, Finance, Human Resources, Legal and Digital.

“My objective has been to find the right blend of talented people that can make the whole team stronger than its individual parts. Sanofi needs people who can bring us new insights from the outside of the industry as well as people with world-class pharma expertise. We need leaders who come to Sanofi with a fresh perspective as well as leaders who have grown up within the company,” says Paul Hudson, Chief Executive Officer at Sanofi. “I am confident in this team’s capacity to inspire our people, execute our strategy and change the practice of medicine for patients.”

Natalie Bickford, Executive Vice President, Chief People Officer

Natalie Bickford starts on August 1, and joins Sanofi from Merlin Entertainments, the world’s second largest location-based entertainment business (which includes Legoland Resorts, Madame Tussaud’s, SEALIFE aquariums, among other brands). At Merlin, she was responsible for 30,000 employees across Europe, North America, and Asia Pacific. Ms. Bickford brings a wealth of consumer-facing experience. She held previous Human Resources leadership positions at Sodexo, AstraZeneca, and Kingfisher, has consistently demonstrated passion for engaging teams and driving change in behaviors and culture. She also has a solid track record of transforming organizations, with a strong focus on inclusion and diversity.

Arnaud Robert, Executive Vice President, Chief Digital Officer (CDO)

Arnaud Robert is currently Chief Digital Officer at Viking Cruises, a cruise line provider. He joins as Sanofi’s CDO on June 15, and will drive Sanofi’s digital, data and technology strategy. As newcomer to the pharma sector, Robert brings a strong background in consumer, omni-channel experience, platform/technology, big data and front-end digital experience. He has held previous leadership positions at The Walt Disney Company and Nike, where he designed and launched the Apple Watch l Nike+ digital community.

Julie Van Ongevalle, Executive Vice President, Head of Consumer Healthcare

Julie Van Ongevalle starts on September 1, replacing Alan Main. She is currently Global Brand President of Origins, a division of the Estée Lauder Companies, based in New York City. With more than 20 years of international experience, Van Ongevalle has built brands, from identifying accelerated growth opportunities, to building and implementing execution plans resulting in sustainable, long-term profitable growth. Her deep knowledge of consumers and digital will be essential as Sanofi advances builds a standalone, agile and multi-local brands Consumer Healthcare business.

Thomas Triomphe, Executive Vice President, Head of Sanofi Pasteur

Thomas Triomphe currently serves as Head of Franchises and Product Strategy for Sanofi Pasteur, and will be promoted to Executive Vice President, Head of Sanofi Pasteur, effective June 15.  Triomphe replaces David Loew. Triomphe joined Sanofi Pasteur in 2004 as part of a talent management program and has since held different roles of increasing responsibility in sales and marketing, at the country, regional, and global levels.

The Company extends sincere thanks to David Loew and Alan Main for their leadership and outstanding contributions. Most recently, both executives have played a critical role in harnessing Sanofi’s efforts and resources in the fight against COVID-19.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Sanofi Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Quentin Vivant

Tél.: +33 (0)1 53 77 46 46





 
 



Sanofi Investor Relations

Felix Lauscher

Tel.: +33 (0)1 53 77 45 45







Attachment

EN
29/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for c...

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, ...

 PRESS RELEASE

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au ...

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a considérablement réduit les exacerbations (de 54 % à 65 %) et amélioré la fonction pulmonaire (de 4,68 % à 5,32 %) par rapport au placeboLe Dupixent est le premier et le seul médicament biologique à démontrer une amélioration de la fonction pulmon...

 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - November 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,438,854,192Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry ...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 438 854 192 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital  Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...

Research Department
  • Research Department
SAN SANOFI
REP REPSOL SA ... (+6)

INFORME DIARIO 22 DICIEMBRE (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AMPER, CAF, FCC, REPSOL. EUROPA: SANOFI. El Ibex continúa imparable Las bolsas europeas cerraron la semana con signo positivo, apoyadas en la mejora del sentimiento económico y la estabilidad en los mercados. El Ibex destacó como el índice más alcista con una subida del 2,0% por encima de los 17.200 puntos. En el STOXX 600, todos los sectores menos Tecnología, Autos y Energía cerraron la semana con ganancias, lideradas por Bancos y R. Básicos. Por ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch